Table 3.
Effects of a “just-in-time” nurse consultation on osteoporosis pharmacotherapy and osteoporosis-related behaviors, knowledge, and self-efficacy compared with matched PAADRN intervention and control participantsa
| Outcome measure | Nurse consultation (n = 104) | PAADRN intervention (n = 39) | PAADRN control (n = 70) | p value (consultation vs intervention) | p value (consultation vs control) |
|---|---|---|---|---|---|
| Proportion with guideline-concordant pharmacotherapy | |||||
| 52 weeks | 0.70 (0.46) | 0.72 (0.46) | 0.67 (0.47) | 0.853 | 0.672 |
| Combined exercise (sessions of exercise per week) | |||||
| Baseline | 3.69 (2.77) | 4.63 (3.18) | 4.44 (2.09) | 0.085 | 0.056 |
| 52 weeks | 4.15 (3.18) | 4.33 (2.93) | 4.91 (2.66) | 0.753 | 0.101 |
| Δ52-BL | 0.46 (2.79) | −0.29 (2.85) | 0.47 (2.16) | 0.153 | 0.980 |
| p value (Δ52-BL) | 0.094 | 0.522 | 0.073 | — | — |
| Total calcium (average daily calcium in diet, mg/d) | |||||
| Baseline | 917.86 (341.81) | 920.97 (339.93) | 990.1 (325.15) | 0.961 | 0.165 |
| 52 weeks | 1030.94 (332.25) | 1012.45 (294.91) | 1026.53 (358.52) | 0.761 | 0.934 |
| Δ52-BL | 113.08 (314.48) | 91.48 (309.57) | 36.43 (293.91) | 0.714 | 0.107 |
| p value (Δ52-BL) | < 0.001 | 0.073 | 0.303 | — | — |
| Proportion with vitamin D supplementation | |||||
| Baseline | 0.58 (0.50) | 0.54 (0.51) | 0.63 (0.49) | 0.682 | 0.499 |
| 52 weeks | 0.59 (0.49) | 0.51 (0.51) | 0.60 (0.49) | 0.432 | 0.860 |
| Δ52-BL | 0.01 (0.43) | −0.03 (0.49) | −0.03 (0.42) | 0.674 | 0.561 |
| p value (Δ52-BL) | 0.820 | 0.744 | 0.567 | — | — |
| Osteoporosis knowledge | |||||
| Baseline | 7.61 (1.81) | 7.26 (2.00) | 7.66 (1.54) | 0.320 | 0.846 |
| 52 weeks | 7.95 (1.63) | 7.58 (1.57) | 7.78 (1.88) | 0.240 | 0.523 |
| Δ52-BL | 0.35 (1.65) | 0.39 (1.74) | 0.09 (1.70) | 0.895 | 0.324 |
| p value (Δ52-BL) | 0.035 | 0.19 | 0.67 | — | — |
| Activation (scale points) | |||||
| Baseline | 58.95 (12.81) | 62.58 (12.92) | 63.63 (14.64) | 0.135 | 0.027 |
| 52 weeks | 75.07 (16.38) | 80.36 (17.52) | 79.66 (17.37) | 0.094 | 0.079 |
| Δ52-BL | 16.12 (19.37) | 17.78 (20.49) | 16.03 (16.72) | 0.654 | 0.974 |
| p value (Δ52-BL) | < 0.001 | < 0.001 | < 0.001 | — | — |
| OSE-Exercise (scale points) | |||||
| Baseline | 8.11 (1.82) | 8.01 (1.61) | 8.3 (1.90) | 0.773 | 0.514 |
| 52 weeks | 8.11 (2.07) | 7.62 (2.15) | 8.43 (1.60) | 0.223 | 0.278 |
| Δ52-BL | 0 (1.63) | −0.39 (2.00) | 0.02 (1.47) | 0.235 | 0.934 |
| p value (Δ52-BL) | 0.985 | 0.232 | 0.895 | — | — |
| OSE-Diet (scale points) | |||||
| Baseline | 8.51 (1.73) | 8.41 (1.34) | 8.77 (1.43) | 0.752 | 0.286 |
| 52 weeks | 8.81 (1.54) | 8.18 (1.84) | 8.94 (1.23) | 0.043 | 0.551 |
| Δ52-BL | 0.29 (1.51) | −0.23 (1.42) | 0.18 (1.33) | 0.068 | 0.645 |
| p value (Δ52-BL) | 0.059 | 0.32 | 0.257 | — | — |
| Osteoporosis care satisfaction (scale points)b | |||||
| Baseline | 19.22 (3.45) | 18.78 (3.96) | 19.37 (3.04) | 0.645 | 0.834 |
| 52 weeks | 21.58 (2.67) | 23.45 (1.57) | 21.41 (3.12) | 0.004 | 0.769 |
| Δ52-BL | 2.41 (3.75) | 4.56 (4.26) | 2.11 (3.01) | 0.045 | 0.694 |
| p value (Δ52-BL) | < 0.001 | < 0.001 | < 0.001 | — | — |
a
Restricted to participants who completed baseline and 52-week interviews. Guideline-concordant pharmacotherapy was assessed only at 52 weeks.
b
Among participants with prior dual-energy x-ray absorptiometry (DXA): 56 in the nurse consultation group, 18 in the PAADRN intervention group, and 35 in the PAADRN control group.
OSE = osteoporosis self-efficacy; PAADRN = Patient Activation After DXA Result Notification; Δ52-BL = change between baseline and 52-week follow-up.